Ascendis Pharma A (ASND) EPS (Basic) (2014 - 2026)

Ascendis Pharma A has disclosed EPS (Basic) across 13 years of filings, most recently posting $62.0 for Q1 2026.

• EPS (Basic) for Q1 2026 came in at $62.0, up 3.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $68.49 (up 49.0% YoY), and the FY2025 annual result was -$4.38, up 37.28% from the prior year.
• EPS (Basic) came in at $62.0 for Q1 2026 at Ascendis Pharma A, up from -$4.09 in the prior quarter.
• In the past five years, EPS (Basic) ranged from a high of $62.0 in Q1 2026 to a low of -$29.58 in Q2 2023.
• The 5-year median for EPS (Basic) is -$1.57 (2023), against an average of $13.52.
• Across the five-year window, EPS (Basic) soared 263.11% in 2022 and tumbled 200.66% in 2024, its largest moves.
• Ascendis Pharma A's EPS (Basic) stood at -$3.7 in 2022, then surged by 57.56% to -$1.57 in 2023, then sank by 200.66% to -$4.72 in 2024, then grew by 13.32% to -$4.09 in 2025, then jumped by 1615.22% to $62.0 in 2026.
• The last three EPS (Basic) figures came in at $62.0 (Q1 2026), -$4.09 (Q4 2025), and -$7.55 (Q3 2025), per Business Quant data.